Research status and therapeutic strategy of giant congenital melanocytic nevus

doi:10.3877/cma.j.issn.1673-9450.2020.04.007

Abstract

Abstract:

Giant congenital melanocytic nevus (GCMN) is defined as a melanotic lesion of the skin that is present at birth and is mainly characterized by a large area of the lesion, infiltration of melanocytes deep in the skin or subcutaneous tissue, with unique histological findings. Most of the patients are sporadic, but familial cases have also been reported, its pathogenesis is still unclear. It often places a serious psychological burden on patients and their families because it severely affects the appearance and may develop into malignant melanoma or neurocutaneous melanosis(NCM). The treatment methods of GCMN include surgical treatment and non-surgical treatment. Different methods have their indications and advantages and disadvantages. The prevention and treatment effect of GCMN are not satisfactory at present. Some studies have preliminarily shown that drug treatment is expected to reduce the incidence of complications and improve the recovery of patients, which can be used as an adjuvant therapy of traditional treatment methods.

Key words: Nevus, pigmented, Skin neoplasms, Diagnosis, Giant congenital melanocytic nevus, Pathogenesis, Complications, Therapeutic strategy

Chiyu Jia, Xialin Cheng. Research status and therapeutic strategy of giant congenital melanocytic nevus[J]. Chinese Journal of Injury Repair and Wound Healing(Electronic Edition), 2020, 15(04): 268-274.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhssyxfzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1673-9450.2020.04.007

https://zhssyxfzz.cma-cmc.com.cn/EN/Y2020/V15/I04/268

References 36

[1]	Mort RL, Jackson IJ, Patton EE. The melanocyte lineage in development and disease[J]. Development, 2015, 142(4): 620-632.
[2]	Cotton CH, Goldberg GN. Evolution of congenital melanocytic nevi toward benignity: A case series[J]. Pediatr Dermatol, 2019, 36(2): 227-231.
[3]	Charbel C, Fontaine RH, Malouf GG, et al. NRAS mutation is the sole recurrent somatic mutation in large congenital melanocytic nevi[J]. J Invest Dermatol, 2014, 134(4): 1067-1074.
[4]	Martins da Silva V, Martinez-Barrios E, Tell-Martí G, et al. Genetic Abnormalities in Large to Giant Congenital Nevi: Beyond NRAS Mutations[J]. J Invest Dermatol, 2019, 139(4): 900-908.
[5]	Salgado CM, Basu D, Nikiforova M, et al. BRAF mutations are also associated with neurocutaneous melanocytosis and large/giant congenital melanocytic nevi[J]. Pediatr Dev Pathol, 2015, 18(1): 1-9.
[6]	Samatar AA, Poulikakos PI. Targeting RAS-ERK signalling in cancer: promises and challenges[J]. Nat Rev Drug Discov, 2014, 13(12): 928-942.
[7]	Stark MS. Large-Giant Congenital Melanocytic Nevi: Moving Beyond NRAS Mutations[J]. J Invest Dermatol, 2019, 139(4): 756-759.
[8]	Pawlikowski JS, McBryan T, van Tuyn J, et al. Wnt signaling potentiates nevogenesis[J]. Proc Natl Acad Sci U S A, 2013, 110(40): 16009-16014.
[9]	Takeo M, Lee W, Rabbani P, et al. EdnrB Governs Regenerative Response of Melanocyte Stem Cells by Crosstalk with Wnt Signaling[J]. Cell Rep, 2016, 15(6): 1291-1302.
[10]	Chitsazan A, Ferguson B, Villani R, et al. Keratinocyte Sonic Hedgehog Upregulation Drives the Development of Giant Congenital Nevi via Paracrine Endothelin-1 Secretion[J]. J Invest Dermatol, 2018, 138(4): 893-902.
[11]	Chitsazan A, Ferguson B, Ram R, et al. A mutation in the Cdon gene potentiates congenital nevus development mediated by NRAS(Q61K)[J]. Pigment Cell Melanoma Res, 2016, 29(4): 459-464.
[12]	Kinsler VA, Anderson G, Latimer B, et al. Immunohistochemical and ultrastructural features of congenital melanocytic naevus cells support a stem-cell phenotype[J]. Br J Dermatol, 2013, 169(2): 374-383.
[13]	Cramer SF, Fesyuk A. On the development of neurocutaneous units-implications for the histogenesis of congenital, acquired, and dysplastic nevi[J]. Am J Dermatopathol, 2012, 34(1): 60-81.
[14]	Charbel C, Fontaine RH, Kadlub N, et al. Clonogenic cell subpopulations maintain congenital melanocytic nevi[J]. J Invest Dermatol, 2015, 135(3): 824-833.
[15]	Ruiz-Maldonado R. Measuring congenital melanocytic nevi[J]. Pediatr Dermatol, 2004, 21(2): 178-179.
[16]	Krengel S, Scope A, Dusza SW, et al. New recommendations for the categorization of cutaneous features of congenital melanocytic nevi[J]. J Am Acad Dermatol, 2013, 68(3): 441-451.
[17]	Martins da Silva VP, Marghoob A, Pigem R, et al. Patterns of distribution of giant congenital melanocytic nevi (GCMN): The 6B rule[J]. J Am Acad Dermatol, 2017, 76(4): 689-694.
[18]	Tannous ZS, Mihm MC Jr, Sober A, et al. Congenital melanocytic nevi: clinical and histopathologic features, risk of melanoma, and clinical management[J]. J Am Acad Dermatol, 2005, 52(2): 197-203.
[19]	Simons EA, Huang JT, Schmidt B. Congenital melanocytic nevi in young children: Histopathologic features and clinical outcomes[J]. J Am Acad Dermatol, 2017, 76(5): 941-947.
[20]	Vergier B, Laharanne E, Prochazkova-Carlotti M, et al. Proliferative Nodules vs Melanoma Arising in Giant Congenital Melanocytic Nevi During Childhood[J]. JAMA Dermatol, 2016, 152(10): 1147-1151.
[21]	Yélamos O, Arva NC, Obregon R, et al. A comparative study of proliferative nodules and lethal melanomas in congenital nevi from children[J]. Am J Surg Pathol, 2015, 39(3): 405-415.
[22]	Viana ACL, Goulart EMA, Gontijo B, et al. A prospective study of patients with large congenital melanocytic nevi and the risk of melanoma[J]. An Bras Dermatol, 2017, 92(2): 200-205.
[23]	Vourc′h-Jourdain M, Martin L, Barbarot S, et al. Large congenital melanocytic nevi: therapeutic management and melanoma risk: a systematic review[J]. J Am Acad Dermatol, 2013, 68(3): 493-498, e1-e14.
[24]	Hale EK, Stein J, Ben-Porat L, et al. Association of melanoma and neurocutaneous melanocytosis with large congenital melanocytic naevi--results from the NYU-LCMN registry[J]. Br J Dermatol, 2005, 152(3): 512-517.
[25]	Kinsler VA, O′Hare P, Bulstrode N, et al. Melanoma in congenital melanocytic naevi[J]. Br J Dermatol, 2017, 176(5): 1131-1143.
[26]	Marghoob AA, Agero AL, Benvenuto-Andrade C, et al. Large congenital melanocytic nevi, risk of cutaneous melanoma, and prophylactic surgery[J]. J Am Acad Dermatol, 2006, 54(5): 868-870; discussion 871-873.
[27]	Jakchairoongruang K, Khakoo Y, Beckwith M, et al. New insights into neurocutaneous melanosis[J]. Pediatr Radiol, 2018, 48(12): 1786-1796.
[28]	Chen Lei, Zhai Liqin, Al-Kzayer Lika′a Fasih Y et al. Neurocutaneous Melanosis in Association With Large Congenital Melanocytic Nevi in Children: A Report of 2 Cases With Clinical, Radiological, and Pathogenetic Evaluation[J]. Front Neurol, 2019, 10: 79.
[29]	Bekiesińska-Figatowska M, Sawicka E, Zak K, et al. Age related changes in brain MR appearance in the course of neurocutaneous melanosis[J]. Eur J Radiol, 2016, 85(8): 1427-1431.
[30]	张辉. 不同术式治疗48例巨痣临床应用研究[D]. 乌鲁木齐：新疆医科大学，2019.
[31]	Mir A, Agim NG, Kane AA, et al. Giant Congenital Melanocytic Nevus Treated With Trametinib[J]. Pediatrics, 2019, 143(3): e20182469.
[32]	Pawlikowski JS, Brock C, Chen SC, et al. Acute Inhibition of MEK Suppresses Congenital Melanocytic Nevus Syndrome in a Murine Model Driven by Activated NRAS and Wnt Signaling[J]. J Invest Dermatol, 2015, 135(8): 2093-2101.
[33]	Küsters-Vandevelde HV, Willemsen AE, Groenen PJ, et al. Experimental treatment of NRAS-mutated neurocutaneous melanocytosis with MEK162, a MEK-inhibitor[J]. Acta Neuropathol Commun, 2014, 2: 41.
[34]	Basu D, Salgado CM, Bauer BS, et al. Nevospheres from neurocutaneous melanocytosis cells show reduced viability when treated with specific inhibitors of NRAS signaling pathway[J]. Neuro Oncol, 2016, 18(4): 528-537.
[35]	Rouillé T, Aractingi S, Kadlub N, et al. Local Inhibition of MEK/Akt Prevents Cellular Growth in Human Congenital Melanocytic Nevi[J]. J Invest Dermatol, 2019, 139(9): 2004-2015, e13.
[36]	Polat Ekinci A, Kiliç S, Baykal C. Pigment Loss in Patients with Large Congenital Melanocytic Nevi: Various Clinical Presentations Documented in a Large Series[J]. Pediatr Dermatol, 2016, 33(3): 307-310.

Please choose a citation manager

Content to export